Neuroblastoma is a paediatric cancer with a poor prognosis. This is in part due to the widespread metastasis at time of presentation, which is refractory to current treatment modalities. New therapeutic agents that can control not only tumour growth but also metastasis are urgently needed.
Background
Neuroblastoma is a paediatric cancer that originates due to delayed development of the neural crest cells destined to form the sympathetic nervous system or adrenal glands [1] . Most patients present with high risk metastatic disease. However patients presenting before 18 months of age have a better prognosis, despite having widespread disease. This is thought to be due in part to the eventual differentiation of tumour cells in younger patients, and has led to the development of differentiation therapy, such as retinoic acid, as a strategy for treating neuroblastoma [2, 3] .
Although the inclusion of retinoic acid in treatment protocols results in enhancement in survival, many patients still relapse. In culture, cell lines with amplification of the MYCN gene typically respond to retinoic acid whilst cell lines or patients with other genetic modifications such as loss of chromosome 11q do not [4] , hence the need for additional treatment options for this group.
Retinoic acid acts by modifying gene expression via complex formation with its receptor RAR and downregulation of MYC-N levels. Hence, it is most effective in inducing differentiation in tumours with high MYCN expression [5, 6] . Retinoic acid also decreases cell proliferation by increasing levels of p27(Kip1), an inhibitor of cyclin D kinase (CDK) 2, 4 and 6 [7] . Decreasing proliferation is thought to be intimately associated with the initiation of differentiation during normal development [8] and this led us to hypothesise that agents directly inhibiting CDKs may provide an additional or alternative approach to promoting differentiation of neuroblastoma cells. CDK inhibitors have previously been tested in a range of tumour types including breast cancer where Palbociclib, a CDK 4/6 inhibitor, has been approved for use in patients [9, 10] . RO-3306, a CDK1 inhibitor, has also been successfully tested in preclinical models [11, 12] .
We have previously developed a chick embryo model to enable the investigation of neuroblastoma growth and its metastatic process. We demonstrated that several neuroblastoma cell lines form tumours on the chick embryo chorioallantoic membrane (CAM) [13] . We have further shown that upon hypoxia preconditioning (1% O 2 ) for three days prior to implantation, cells metastasised into the chick embryo from 60% of the tumours observed [13] . This model has further been shown to be suitable for therapeutic agents testing [14] . We therefore used it to test whether CDK inhibitors, known to slow cell proliferation, may also reduce or prevent metastasis.
Results

CDK4/6 inhibitor promotes differentiation of BE(2)C cells while CDK1 inhibitor promotes cell death.
Previous work has shown that all-trans retinoic acid (ATRA) promotes cell differentiation and reduces cell proliferation in some neuroblastoma (NB) cell lines, possibly by increased expression of p27Kip1, an inhibitor of CDK2, 4 and 6 [7] . CDK inhibitors, which are known to slow the cell cycle, may therefore promote the differentiation of neuroblastoma cells. To test this hypothesis, BE(2)C cells were treated with the CDK4/6 inhibitor Palbociclib (CDK4/6i) for 3 days, alone or in combination with ATRA to test whether the CDK4/6i might enhance the ATRA effects on neuroblastoma differentiation. In terms of morphology, while 5 µM of CDK4/6i promoted the growth of cell extensions similar to those seen with ATRA, doses of 10 µM and above promoted cell death ( Figure   1A ). Treatment with 5 µM CDK4/6i was enough to reduce the proliferation of BE(2)C cells by 59% essentially similar to the ATRA effects ( Figure 1B ). The combination of the CDK4/6i and ATRA did not further decrease cell proliferation ( Figure 1C ), suggesting that these 2 drugs have similar mechanisms of action. To confirm that CDK4/6i was driving BE(2)C cell differentiation, the expression of previously characterised markers KLF4, ROBO2 and STMN4, [14] was measured. In all three conditions (drugs alone or in combination), the expression of the stem cell marker KLF4 decreased whilst the expression of the differentiation markers ROBO2 and STMN4 increased compared to untreated cells. Again, CDK4/6i was no more potent than ATRA alone ( Figure 1D ). The expression of MYCN was not significantly altered in response to the CDK4/6i, whereas a small decrease was observed in response to ATRA ( Figure 1D ). CDK4/6 acts at the G1/S boundary, whereas CDK1 acts at both the G1/S and G2/M boundaries. We therefore further tested whether a CDK1 inhibitor would have a similar effect to the CDK4/6 inhibitor. BE(2)C cells were treated for 3 days with RO-3306, a CDK1 inhibitor. Based on morphology, unlike CDK4/6i, RO-3306 promoted cell death in contrast to inhibition of proliferation and/or promotion of differentiation even at 5 µM (Figure 2A ). At 1 µM there was no change in morphology and no evidence for cell death (data not shown). Twenty four hour treatment of BE(2)C cells with 5 µM RO-3306 followed by two days without drug also resulted in cell death rather than any morphological indication of differentiation (data not shown). To quantify this further, we determined cell viability after 3 days and showed that RO-3306 was indeed effective at reducing cell viability ( Figure 2B ). Three day treatment with 5 µM CDK1i reduced cell viability by 65% and increasing the concentration of the inhibitor did not enhance this further. Using Annexin V labelling, we demonstrated that the cell death was apoptotic ( Figure 2C ). We also noticed that 5 µM CDK4/6i, shown above to promote differentiation, also prompted cell death by apoptosis of some cells ( Figure   2C ).
CDK4/6 and CDK1 inhibitors promote cell death of SK-N-AS cells
SK-N-AS cells express MYCN but do not have amplification of the MYCN gene. Instead they have an 11q deletion and thus represent the genetic signature of another group of patients with poor prognosis [4] . SK-N-AS cells do not differentiate or indeed respond to ATRA alone [15] so being able to target 11q-cells with an alternative approach would be very beneficial. As shown in Figure 3A the response of the SK-N-AS to both CDK4/6i and CDK1i was cell death at 5 µm, with no evidence of a change in morphology towards a differentiation phenotype at lower doses (1 µm). Cell viability was assessed after three days and again CDK1i prompted extensive cell death (58%) at 5 µM with no significant increase at higher concentrations ( Figure 3B ). CDK4/6i was less efficient in inducing cell death at 5 or 10 µM ( Figure 3B ), but there was still evidence of increased apoptosis at 5 µM ( Figure   3C ).
CDK4/6 and CDK1 inhibitors reduce cell proliferation in both BE(2)C and SK-N-AS tumours
Cells can respond differently to drugs in a 3D in vivo environment compared to a 2D culture, so it was essential to test the efficacy of these drugs on tumours formed in vivo. We have used the chick CAM model, which not only allows robust neuroblastoma tumour formation, but also the control of their metastatic phenotype through hypoxic preconditioning [13] . We have previously shown that using four times the in vitro concentration of ATRA in the chick, tumours had significantly reduced number of proliferating cells, with cells also expressing differentiation markers [14] . We injected CDK inhibitors to give a concentration of 20 µM (in the egg), after tumour formation at embryonic day 11 (E11) and E13 and the treated tumours were harvested at E14. The chick embryos tolerated the doses well with no significant change in embryo survival (data not shown). Ki67-staining of BE(2)C tumour sections revealed a reduction in cell proliferation in response to both CDK4/6i and CDK1i ( Figure 4A and C). CDK4/6i reduced cell proliferation of BE(2)C cells by 35%, similar to ATRA (39%) ( Figure 4B ). Contrary to in vitro data, CDK1i proved more efficient than CDK4/6i, reducing cell proliferation by almost 50%. Similar experiments were carried out with SK-N-AS cells. Since ATRA has no effect on SK-N-AS [15] , only the two CDK inhibitors were tested. The reduction in proliferation was similar to that seen with BE(2)C cells (40% and 50% for CDK1i and CDK4/6i respectively; Figure 4D ).
Since, both inhibitors had a marked effect on cell survival and triggered apoptosis in cultured cells, we used TUNEL staining to evaluate the amount of apoptosis in the tumours. The number of cells dying by apoptosis was very small in control tumours (<2%). This result was consistent with the number of apoptoticcells observed by histology (Supplementary figure) . None of the inhibitors triggered a significant increase in either BE(2)C or SK-N-AS tumours (Figure 4 E,F) . Thus, unlike in in vitro cell culture, the main effect of the CDK inhibitors was a reduction in cell proliferation, rather than an increase in apoptosis
CDK inhibitors reduce hypoxia/DMOG-induced metastasis
We next investigated the effects of the CDK inhibitors on neuroblastoma metastasis. We have previously shown that preconditioning neuroblastoma cell lines for three days in 1% O 2 or pretreatment for 24 h with the hypoxia mimetic drug DMOG promotes metastasis of cells from the tumour formed on the CAM into the embryo [13] . Prior to the in vivo investigation, we initially tested whether ATRA could reverse the effect of DMOG on the BE(2)C cells proliferation in vitro. As shown in Figure 5A We further tested the CDK inhibitors and ATRA, for their ability to block the metastatic process in vivo. We have previously shown that by pre-treating cells with DMOG for 24 h or growing cells in 1% O 2 for 3 days prior to implanting the cells on the CAM, triggered metastasis in 60% of the cases, often in the liver and gut [13] . Such a metastatic phenotype was never observed with tumours formed from cells grown in normoxia. Before testing the effect of the drugs we first needed to determine the onset time of metastatic dissemination by dissecting the embryos at E9 -E13.
Tumour formation could first be detected at E11 for BE(2)C cells and E10 for SK-N-AS cells, yet in most cases metastatic cells were only observed after E12. We therefore changed the treatment regime from injections at E11 and E13 to E10 and E12 to ensure that the inhibitors were introduced before to the onset of metastasis. Figure 7A ). We initially observed that DMSO alone had an impact on metastasis occurrence. DMSO above 100 µl in total is reported to compromise chick survival [16] and although chick survival was not affected in our hands with a final volume of 130 µl, it did reduce the ability of tumour cells to metastasise. We reduced the number of injections from two to one and with a single injection of CDK1i or DMSO at E10, the effects of DMSO were comparable to PBS controls and significantly different to the CDK1i ( Figure 7C ; 80% metastasis with DMSO alone versus 33% with CDK1i). CDK4/6i was dissolved in PBS, but for comparison, we also gave only one injection at E10. In this case the metastasis frequency was reduced from 92% to 44% ( Figure 7C ).
Similar experiments were conducted with BE(2)C cells. The distribution of metastatic cells was similar to that observed for SK-N-AS ( Figure 7B ) and CDK1i reduced metastasis by almost 60% (from 76% to 31%) while CDK4/6i reduced metastasis by 56% (from 83% to 36%) ( Figure 7D ). ATRA was introduced into the allantoic sac in 11.5 µl of DMSO (due to the greater solubility of ATRA in DMSO).
Its effect with one and two injections was measured as comparison. One injection reduced metastasis from 80% to 60% while two injections reduced it from 64% (two injections of DMSO) to 27%. Thus ATRA was less efficient at reducing metastasis than either of the CDK inhibitors but it was interesting that the second injection was able to significantly reduce metastasis supporting the notion that metastasis was mainly occurring between E12 and E14 in this model ( Figure 7D ).
CDK1i partially reverses hypoxia driven changes in gene expression
We have previously observed significant changes in the expression of more than 20 genes thought to be important in the metastatic process in response to both hypoxia and DMOG pre-conditioning [13] . In order to provide some insight into the mechanism by which the CDK inhibitors might be acting on the metastatic process, we selected eight of these genes to test for their response to CDK1i proliferation. The cellular response to agents in the complex 3D environment of a tumour can be different to that seen in 2D cultures as has been observed by others [17, 18] and this may be the more likely explanation for the differences observed demonstrating yet again the value of the in vivo model. Metastasis was judged to have occurred if fluorescent cells were found in the embryo by dissection under a fluorescent stereomicroscope. Single cells within in the embryo could be identified making this more efficient than previous methods of detecting metastatic cells [19] .
Careful dissection of many embryos here and previously [13, 14] revealed the typical locations for the metastatic cells. The most common locations were associated with the intestines in the peritoneal cavity or the liver. No metastatic cells were seen prior to the formation of a primary tumour on the CAM and they were only seen in embryos that formed a primary tumour. This confirms that the cells within the embryo were derived from the primary tumour rather than from the initial implantation of cells on the CAM at E7 [13, 14, [20] [21] [22] [23] . Thus the CAM tumour model is excellent for investigating response mechanisms to new therapeutic agents in a cost-effective and timely manner.
CDK1:cyclin B complex is sufficient to drive mammalian cells through the cell cycle via phosphorylation of Rb and the consequent activation of the E2F expression program [24] . Inhibiting CDK1 generally arrests the cell cycle at the G2/M boundary and can result in cells undergoing apoptosis [25] .Thus CDK1 makes an attractive target although it should be noted that CDK1 is also responsible for a key phosphorylation step that primes MYCN for degradation [26] . CDK4/6 promotes progression through the G1/S boundary also by phosphorylation of Rb. Components of the CDK4/6 pathway are often dysregulated in cancer making this complex a promising target for treatment [27] . Like CDK1, CDK4 and 6 activate a number of additional pathways and the consequence of inhibiting these kinase may be variable in different tumours [27] . The Inhibitor palbociclib has variable sensitivity across a number of neuroblastoma cell lines [28] , furthermore, LEE011, an alternative CDK4/6 inhibitor prompted apoptosis in the majority of neuroblastoma cell lines tested and a reduction in proliferation in BE(2)C xenograft tumours in mice [29] consistent with our results.
Hypoxia drives an aggressive, invasive phenotype and many effects are mediated by HIF1-α. Targets of HIF1-α include proteins involved in invasion, intravasation, adhesion and extravasation and these are likely to be responsible for the change in the neuroblastoma cells to a metastatic phenotype.
CDK1, 4 and 6 have been shown to directly increase the stability of HIF1-α by two different mechanisms. CDK1 phosphorylates HIF1-α on Ser688, a modification that reduces the degradation of HIF1-α [30] . CDK4/6 phosphorylates prolyl hydroxylase 1 (PHD1), one of the enzymes responsible for degrading HIF1-α in the presence of O 2 [31] . Phosphorylation alters the interaction between PHD and HIF1-α potentially stabilising HIF1-α. Both these CDK activities occur independently of O 2 levels.
Inhibiting these CDKs is expected to reduce the abundance of HIF1-α, an effect that should be most obvious under hypoxic conditions when HIF1-α is normally stabilised. Here we find that treatment with the CDK1i, RO-3306, can partially reverse the hypoxia-induced expression pattern in the tumour several days after this pattern has been established in culture.
Blocking the cell cycle via CDK inhibitors is an attractive approach to treating many cancers and had the added value here of potentially prompting differentiation. Some neuroblastoma cell lines and some tumours respond well to retinoic acid by adopting a less aggressive more differentiated phenotype and it is well established that tumours with differentiation markers such as TrkA have a better prognosis. SK-N-AS, along with a number of other cell lines, has not been shown to differentiate so far. However, since both CDK inhibitors reduced cell proliferation in the SK-N-AS CAM tumours, a prerequisite to initiating differentiation, it would be interesting to investigate whether the cells did begin to move down the differentiation pathway in vivo.
In conclusion, CDKi provide promising alternatives to ATRA for both reduction of tumour development but also of its dissemination. In addition, they have the potential to be effective in a range of neuroblastoma genetic background, and unlike ATRA, are not restricted to MYCN amplified tumours. The fact that they have been trialled in clinic for other tumour types should facilitate their deployment for neuroblastoma in a near future.
Methods and Materials:
Cell culture BE(2)C (human NB, ECACC No. 95011817) and SK-N-AS (human NB, ECACC 94092302) were grown in minimal essential medium DMEM (Life Technologies), 10% Foetal Bovine Serum FBS (Biosera, East Sussex, UK ), 100 U/ml penicillin,100 μg/ml streptomycin ( Sigma, P0781) and 1% Non-Essential Amino Acids (Sigma, M7145). They were maintained at 37°C with 5% CO 2 were passaged using 0.05% Trypsin/EDTA (Sigma Aldrich). Cell lines were transduced with green fluorescent protein (GFP) lentivirus as described previously [13, 22] . For hypoxic studies, cells were maintained at 37 °C with 5% CO 2 
MTT assay
The MTT assay was used to measure cell viability after Palbociclib and CDK1i treatment. BE(2)C cells and SK-N-AS cells were seeded at 5x10 4 cells/ml into 96 well plates (Costar, Cat no. 3596) with 100 μl of medium and left to adhere for 18-24 h at 37°C 5% CO 2 . Cells were cultured in media supplemented with or without 0.5 mM DMOG for 24 h. Cells were then treated for a further 72 h with medium containing Palbociclib or CDK1i. To analyse cell viability, 5 μl of (5 mg/ml) MTT (Sigma)
was then added to each well (100 μl), for 4 h at 37 °C. 100 μl of stop solution (10% SDS in 0.01 M HCl) was added for 1 min. The plate was incubated at 37°C and 5% CO 2 overnight and absorption at 570 nm was read. All MTT assays were repeated three times. 
Apoptosis determination in unfixed cells
Chick embryo CAM Assays
Fertilised white leghorn chicken eggs were obtained from Tom Barron, Preston, UK. Eggs were incubated at 38°C and 35-40% humidity and windowed at E3 as described previously [22] . For tumour formation 2x10 6 GFP-labelled cells were applied to the CAM of each embryo [13] . To increase the tumour yield, the CAM was traumatised using a strip of sterile lens tissue causing a small bleed [32] followed by the addition of 5 µl of 0.05% trypsin 0.5mM EDTA. Eggs were resealed and incubated until E14 [23] . Ethical approval for all experiments involving chick embryos was obtained from the Liverpool Animal Welfare and Ethical Review Body. and three technical replicates and at least three biological replicates were carried out for each sample. qPCR data analysis was carried out using Bio-Rad CFX Manager 3.0 software. Normalised relative expression of target genes compared to housekeeping genes (GAPDH, HPRT1 and UBC) was calculated using the ΔΔCq analysis mode [33] .
In vivo: tumours formed from normoxic cells, hypoxic cells and hypoxic cells after CDK1i application at E10 (20 µM) were harvested from the CAM, rinsed in phosphate-buffered saline (PBS), then transferred into RNAlater solution (QIAGEN), and stored at initially at 4°C or -20°C for longer term storage prior to RNA extraction. Tissue was first removed from the RNAlater and transferred to a clean RNase free falcon tube. Liquid nitrogen was used to freeze the tissue before a pestle and mortar was used to disrupt it. RNA was then extracted using RNA mini Kit (QIAGEN). qPCR was performed as described above. A list of the primers used is provided in Table 1 .
One tumour for each condition (normoxia, hypoxia, hypoxia followed by injection of 200 µl of 4.5 mM CDK1i at E10 or hypoxia followed by 200 µl of 32.5% DMSO at E10) was obtained from a single experiment and fold change was analysed. The experiment was repeated three times and statistical analysis performed on the fold change derived from each experiment.
Immunohistochemistry
Tumours harvested for paraffin embedding were fixed for 2 h in 4% paraformaldehyde (PFA) or 10%
formalin and then embedded in paraffin using standard protocols. 4 µm sections underwent antigen retrieval and were stained using the DAKO Autostainer (K8012) as described previously [14] .
Sections were incubated for 30 min with Ki67 antibody (1:200) (DAKO M7240) in 5% BSA in Tris Buffered Saline followed by goat anti-mouse HRP (Abcam)(1:250) and staining with 3,3'-diaminobenzidine DAB (1 drop per ml). Haematoxylin staining was performed on all the slides to assist in distinguishing between tumour and chick nuclei. A total of 9 fields from 3 slides were counted per tumour and at least three tumours per condition were analysed.
TUNEL Assays
TUNEL assay was performed on tumour sections prepared as above using the DeadEnd™ Colorimetric TUNEL System (G7130) kit according manufacturer's instructions (Promega, Madison, WI, USA). TUNEL-positive nucleus was identified as apoptotic cells. Cell counting was performed on at least three tumours per condition, 9 fields from 3 slides per tumour were counted and analysed.
Statistical analysis
Statistical significance was computed using Student's t-test or one-way ANOVA followed by a posthoc tukey test using SPSS. All data are presented as mean ±SEM. (standard error of the mean).
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